Methotrexate showed no clear difference in serious adverse events compared with placebo (moderate certainty).
Methotrexate probably leads to higher significant adverse events compared with placebo (moderate certainty).
It is very uncertain whether methotrexate changes adverse events (Ardizzone 2003) compared with 6‐MP or azathioprine (very low certainty).
Methotrexate showed no clear difference in serious adverse events(4 months) compared with alternative disease‐modifying antirheumatic drugs (low certainty).
Oral methotrexate may leads to higher adverse events: minor compared with oral chloroquine (low certainty).
Oral methotrexate showed no clear difference in adverse events: minor compared with placebo (moderate certainty).
Methotrexate showed no clear difference in serious adverse events(up to 6 months) compared with placebo (low certainty).
Oral methotrexate showed no clear difference in adverse events: severe compared with oral chloroquine (low certainty).
Oral methotrexate showed no clear difference in adverse events: severe compared with placebo (moderate certainty).
Methotrexate showed no clear difference in withdrawals due to adverse events(4 months) compared with alternative disease‐modifying antirheumatic drugs (low certainty).
Methotrexate showed no clear difference in withdrawals due to adverse events (up to 6 months) compared with placebo (low certainty).
Methotrexate showed no clear difference in serious adverse events (SAEs) assessed by number of events compared with placebo (low certainty).
Methotrexate showed no clear difference in withdrawals due to adverse events (WAEs) assessed by number of events compared with placebo (low certainty).
The review found no eligible studies for this question.
It is very uncertain whether methotrexate + infliximab changes adverse events (Schröder 2006) compared with infliximab alone (very low certainty).
It is very uncertain whether methotrexate + infliximab changes serious adverse events (Schröder 2006) compared with infliximab alone (very low certainty).